STALICLA Archives | Be Korea-savvy
Home / Posts tagged STALICLA
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD

Geneva, Switzerland, March 27 (Korea Bizwire) – STALICLA SA and Firefly Neuroscience today announced a partnership to further validate EEG-based biomarkers in biologically enriched subgroups of patients with Autism Spectrum Disorder (ASD). This follows the successful completion of STALICLA’s Phase 1b clinical trial for its lead asset STP1 where EEG measurement was shown to be a powerful predictor of [...]

STALICLA Signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to Cover Phase 3 Development of Mavoglurant in Cocaine Use Disorder

STALICLA Signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to Cover Phase 3 Development of Mavoglurant in Cocaine Use Disorder

Geneva, Switzerland, March 8 (Korea Bizwire) – STALICLA SA, a clinical stage biotech advancing the first precision neurobiology platform (DEPI) for patients with neurodevelopmental and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). The [...]

STALICLA Signs Exclusive In-licensing Agreement for Late-stage Clinical Neuropsychiatric and Neurodevelopmental Disorder Treatment

STALICLA Signs Exclusive In-licensing Agreement for Late-stage Clinical Neuropsychiatric and Neurodevelopmental Disorder Treatment

Geneva, SWITZERLAND, Jan. 9 (Korea Bizwire) – STALICLA SA, a clinical-stage biotech company advancing the first precision neurobiology platform for patients with neurodevelopmental disorders, today announced that it has entered into an exclusive in-licensing agreement with Novartis to develop mavoglurant as a treatment for substance-use disorder and neurodevelopmental disorders (NDDs). Mavoglurant has previously been tested in more than 1,800 [...]